| 3.61 -0.12 (-3.22%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.93 |
1-year : | 5.63 |
| Resists | First : | 4.22 |
Second : | 4.82 |
| Pivot price | 4 |
|||
| Supports | First : | 3.25 | Second : | 2.7 |
| MAs | MA(5) : | 3.76 |
MA(20) : | 4.14 |
| MA(100) : | 5.24 |
MA(250) : | 4.76 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 29.7 |
D(3) : | 33.9 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 11.96 | Low : | 2.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NDRA ] has closed above bottom band by 21.8%. Bollinger Bands are 26.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.77 - 3.8 | 3.8 - 3.83 |
| Low: | 3.41 - 3.45 | 3.45 - 3.47 |
| Close: | 3.57 - 3.62 | 3.62 - 3.65 |
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Thu, 29 Jan 2026
ENDRA Life Sciences (NASDAQ: NDRA) Gaining Attention as HYPE Token Surges See Why Now! FEED, SER, TRX, XHLD, BATL Inside - Barchart.com
Mon, 15 Dec 2025
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech - openPR.com
Thu, 04 Dec 2025
ENDRA (NASDAQ: NDRA) study supports TAEUS Liver as low-cost MRI-PDFF alternative - Stock Titan
Fri, 21 Nov 2025
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker - BioSpace
Mon, 17 Nov 2025
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results - Business Wire
Mon, 13 Oct 2025
NDRA Stock Price Jumps: What’s Next? - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 36.2 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 78 (K) |
| EPS | 18.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -102 % |
| Return on Equity (ttm) | -236.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0.19 |
| PEG Ratio | 0 |
| Price to Book value | 16.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|